01 — At a Glance
The Queen of Hygiene, Pricing Like She Owns Your Bathroom
- 52-Week High / Low₹14,543 / ₹10,595
- TTM Revenue₹4,341 Cr
- TTM PAT₹859 Cr
- EPS (TTM)₹265
- Annualised EPS (Q3×4)₹371.48
- Book Value₹287
- Price to Book37.1x
- Dividend Yield1.59%
- Debt / Equity0.00x
- ROE (3yr avg)78.6%
The Math Check-In: P&G Hygiene closed Q3 FY26 with ₹1,262 crore revenue (up 1% QoQ), ₹301 crore PAT (up 12% QoQ), and a P/E of 40.2x. The dividend yield is 1.59%, meaning you’re buying a high-growth FMCG brand at a bargain price… except there’s no growth. TTM revenue: ₹4,341 Cr. TTM PAT: ₹859 Cr. Profit growth over 3 years: flat to negative. But ROCE at 104%? That part is legit. The brand moat is real. The price is… ambitious.
02 — Introduction
Welcome to the Land Where Femcare Is Destiny and Cough Drops Are Dividend ATMs
Let’s talk about P&G Hygiene. Founded as Richardson Hindustan in 1964, acquired by Procter & Gamble in 1985, and currently a ₹34,526 crore market-cap beast that literally sells period pads and throat lozenges. Not exactly the stuff of venture capital deck glamour. And yet — 104% ROCE. 78.6% ROE over three years. 89.3% dividend payout. A 50% market share in femcare and cough-and-cold categories that will exist forever.
P&G Hygiene does not disrupt. It does not pivot. It does not have a “platform” or a “D2C digital narrative.” What it does is print cash from a business model that’s been perfected over four decades: take global IP from the world’s most boring—and therefore most profitable—FMCG conglomerate, ship it to India, buy shelf space, and watch a nation’s hygiene habits fund your retirement.
Q3 FY26 delivered ₹1,262 crore in quarterly revenue (barely up 1% YoY). PAT at ₹301 crore climbed 12% QoQ, but the TTM growth figures paint the real picture: revenue flat at ~1%, profit growth at 20% (but from a falling base in prior years). The stock returned -19.4% over one year, -13.6% over three months, yet hit 52-week highs of ₹14,543. Welcome to the premium FMCG paradox.
For value investors, this is the investment equivalent of watching someone pay ₹50,000 for a Maruti Swift with full service warranty and zero repairs needed. For growth investors, this is a career-ending nightmare. We’ll break down which camp you belong in.
The Dividends Thing: P&G Hygiene has declared an interim dividend of ₹195/share (including ₹25 special) for Q3. That’s 1.83% yield alone on CMP. Payout ratio: 89.3% of TTM earnings. The company literally returns almost all profits to shareholders. Capex is minimal. The business runs itself.
03 — Business Model: WTF Do They Even Do?
Three Brands. Two Categories. One Margin Empire.
P&G Hygiene operates a portfolio of three global brands in two core markets: (1) Whisper (femcare, 70% of revenue), (2) Vicks (health care / cough-and-cold, 30%), and (3) Old Spice (male grooming, nascent, sub-5% probably).
Whisper is India’s market leader in sanitary pads. Market share: 50%. Launched in 1992, it’s been the dominant choice for urban and semi-urban India for three decades. The femcare market is growing at 6–8% annually, driven by rising penetration, income growth, and (slowly) period-positivity messaging. Whisper has added innovations: Whisper Ultra XL for heavy flow, Whisper Period Panties for comfort, Whisper Bindazzz Nights (because premium positioning = extra ‘z’s).
Vicks is India’s No. 1 brand in cough-and-cold remedies. Market share: 50%. VapoRub is the household staple your grandma used, your mom used, and your kids will use. VapoRub is to cough medicines what Aspirin is to painkillers — the first thing a family buys. New products: Vicks ZzzQuil (sleep supplement), Vicks Roll On for headaches, Vicks VapoRub Steam Pods (because regular VapoRub was too straightforward).
Old Spice is the American male grooming portfolio acquired globally by P&G. In India, it’s still a niche play but being pushed hard through e-commerce and modern retail.
Manufacturing is lean: two owned plants in India (Silvassa, Nashik) plus contract manufacturing. Workforce: 421 permanent employees as of Mar 2025. Distribution: 39 dealers/distributors reaching 1+ million retail stores. The cash conversion cycle is negative 138 days — meaning P&G collects from retailers 138 days before paying suppliers. Working capital is free money.
Whisper50%Femcare Share
Vicks50%Cough & Cold
Old Spice<5%Grooming
Ad Spend13.5%% of Revenue
The Innovation Game: P&G Hygiene is adding premium products faster than they’re adding revenue. Steam Pods. Period Panties. Sleep supplements. Heavy-flow pads. These are all trying to move needle on a flat revenue growth chart. Management insists “double-digit growth expected in femcare for next 3 years.” Markets yawn. Investors wait.
💬 Do you think premium innovations (like Period Panties) can unlock hidden demand in femcare, or is the market just saturated? Drop your thoughts!
04 — Financials Overview
Q3 FY26: The Numbers That Whisper Disappointment
Result type: Quarterly Results | Q3 FY26 EPS: ₹92.87 | Annualised EPS (Q3×4): ₹371.48 | TTM EPS: ₹265 | P/E (CMP/TTM EPS): 40.2x
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,262 | 1,248 | 1,150 | +1.1% | +9.7% |
| Operating Profit | 402 | 371 | 285 | +8.4% | +41.1% |
| OPM % | 32% | 30% | 25% | +200 bps | +700 bps |
| PAT | 301 | 269 | 210 | +12.3% | +43.3% |
| EPS (₹) | 92.87 | 82.74 | 64.65 | +12.2% | +43.6% |
The QoQ Story (That Matters): Q3 smashed Q2 on every metric — revenue +9.7%, OPM +700 bps, PAT +43.3%, EPS +43.6%. This is where P&G Hygiene really lives: in the quarterly bounce. Q1 & Q2 are always weak (monsoon, inventory sell-off). Q3 & Q4 are always stronger (festive, restocking). So when YoY growth is 1%, but QoQ growth is 10%, what does that tell you? The underlying trend is flat. The stock is a seasonal trade, not a growth story.
05 — Valuation: Fair Value Range
What’s This 40x P/E Actually Worth?
Join 10,000+ investors who read this every week.
